与PD-1抑制剂相关的外围神经病变的患病率:一项回顾性队列研究
Suma Ganji-Angirekula1, Nicole W Segada2, Prit Hasan3
1Department of Emergency Medicine, UTHealth Houston McGovern Medical School, Houston, TX 77030, USA.
Life (Basel, Switzerland)
|January 28, 2026
概括
编程细胞死亡蛋白1 (PD-1) 抑制剂免疫疗法可以导致外围神经病变. 这项研究发现6.76%的患病率,在某些种族和族裔中风险更高,在吸烟者中风险更低.
科学领域:
- 在瘤学瘤学.
- 神经学 神经学
- 免疫治疗是一种免疫疗法.
背景情况:
- 免疫疗法,特别是编程细胞死亡蛋白1 (PD-1) 抑制剂,提供了显著的癌症治疗益处.
- 一个值得注意的副作用是外围神经病变的发展,影响患者的生活质量.
- 了解PD-1抑制剂相关多神经病变的患病率和风险因素对于患者管理至关重要.
研究的目的:
- 确定与使用PD-1抑制剂相关的外围神经病变的流行率和流行病学特征.
- 确定与这种不良事件发展相关的人口和临床因素.
主要方法:
- 从MD安德森癌症中心使用电子医疗记录 (EMR) 的回顾性,横截面研究.
- 分析了2016年3月至2023年6月期间接受PD-1抑制剂治疗的12,092名患者,重点关注免疫疗法单疗法.
- 数据的分层化,以评估神经病变与患者因素之间的关联,包括种族,种族,吸烟和糖尿病状况.
主要成果:
- 在12,092名患者中,在817名患者中观察到6.76% (95% CI 6.31-7.22) 的PD-1抑制剂相关神经病变的患病率.
- 确定为"其他"种族的患者 (OR 1.514,p=0.0189) 和非西班牙裔/拉丁裔患者 (OR 1.502,p=0.0078) 的患病率更高.
- 与从未吸烟者相比,目前吸烟者的神经病变患病率明显较低 (OR 0.716,p=0.0368).
结论:
- 这项研究强调了PD-1抑制剂相关的外围神经病变的患病率的显著差异,基于种族,种族和吸烟状况.
- 这些发现强调了进一步研究潜在的遗传和机械因素的必要性.
- 识别这些机制对于开发有针对性的治疗干预来减轻接受免疫治疗的癌症患者神经病变风险至关重要.
相关概念视频
Prevalence and Incidence
1.8K
In statistical epidemiology and health sciences, two essential metrics—prevalence and incidence—are fundamental for understanding disease dynamics within a population. These measures enable public health officials, epidemiologists, and researchers to assess the burden of diseases, allocate resources effectively, and design impactful public health policies and interventions.
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
1.8K
Eukaryotic Transcription Inhibitors
11.0K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
PD Controller: Design
650
In automotive engineering, car suspension systems often employ Proportional Derivative (PD) controllers to enhance performance. PD controllers are utilized to adjust the damping force in response to road conditions. A controller, acting as an amplifier with a constant gain, demonstrates proportional control, with output directly mirroring input.
Designing a continuous-data controller requires selecting and linking components like adders and integrators, which are fundamental in Proportional,...
Designing a continuous-data controller requires selecting and linking components like adders and integrators, which are fundamental in Proportional,...
650
Time-Domain Interpretation of PD Control
396
Proportional-Derivative (PD) control is a widely used control method in various engineering systems to enhance stability and performance. In a system with only proportional control, common issues include high maximum overshoot and oscillation, observed in both the error signal and its rate of change. This behavior can be divided into three distinct phases: initial overshoot, subsequent undershoot, and gradual stabilization.
Consider the example of control of motor torque. Initially, a positive...
Consider the example of control of motor torque. Initially, a positive...
396
Frequency-Domain Interpretation of PD Control
364
Proportional-Derivative (PD) controllers are widely used in fan control systems to improve stability and performance. A fan control system can be effectively represented using a Bode plot to illustrate the impact of a PD controller through its transfer function. The Bode plot visually conveys how PD control modifies the fan's response across various frequencies, providing a frequency domain interpretation of the controller's behavior.
The proportional control gain, combined with the...
The proportional control gain, combined with the...
364
Dipeptidyl Peptidase 4 Inhibitors
644
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
644


